RxDoctor Payments Data

Christopher Granger, MD

Cardiovascular Disease · Durham, NCNPI 1295818458

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $188,666 of the $256,517 with a category attached, or 73.5%. It is spread thinly across 23 manufacturers, the largest accounting for just 16.2%. Reporting peaked in 2019 at $103,928 and has fallen 68.1% since, to $33,165 in 2025. Among cardiovascular disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$256,517in general payments, 2019–2025

Across 207 payments — averaging $1239.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$42K
  • Janssen Research & Development, LLC$39K
  • Novo Nordisk$35K
  • Medtronic$32K
  • Boehringer Ingelheim$24K
  • Pfizer$15K
  • plus $71K from 17 others
$24,485,063in research payments, 2019–2025

Across 102 payments — averaging $240,050 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alnylam Pharmaceuticals Inc.$16.9M
  • Boehringer Ingelheim$6.6M
  • Philips North America LLC$886K
  • Novo Nordisk AS$52K
  • Novartis Pharma AG$46K
  • GSK$43K
  • plus $43K from 3 others

What the payments were for

  • Consulting fees$188,66674%
  • Speaking & faculty fees$32,97213%
  • Travel & lodging$29,09511%
  • Food & beverage$5,7852%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$256,517 in reported general payments places this provider in the 95th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$40,450
Medicare patients
163
Services billed
358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin54$48,161
EliquisApixaban37$44,394
OzempicSemaglutide14$12,824
Candesartan Cilexetil26$954
Metoprolol Succinate48$786
Atorvastatin Calcium44$452
Losartan Potassium24$343
Rosuvastatin Calcium41$335
Amlodipine Besylate19$249
Carvedilol23$221
Spironolactone33$187
Isosorbide Mononitrate ErIsosorbide Mononitrate12$43
ClopidogrelClopidogrel Bisulfate12$20
Lisinopril19$14

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$23,586$48,16154 claims
PfizerEliquis$14,660$44,39437 claims
Novo NordiskOzempic$34,860$12,82414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →